EVALUATING THE LONG-TERM COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE VERSUS ONCE-DAILY LIRAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES IN THE UK